Reported by Jules Levin | AASLD | Nov 9-13 2012 Boston
High Rate of Sustained Virologic Response With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) Plus Sofosbuvir (Nucleotide NS5B Inhibitor), With or Without Ribavirin, in Treatment-Naive Patients Chronically Infected With HCV GT 1, 2, or 3
Recent data from the Boston AASLD meeting confirm the spectacular Phase II combination results of Gilead’s sofosbuvir administered with BMS’ daclatasvir. (See results). These are truly amazing SVR rates which are much better than the current standard of care and without the use of the dreaded combination of interferon and ribavirin. Thousands of patients were so very hopeful about the possibility of quick access to this much more safe and effective, easily administered HCV drug combination.
How can Gilead Sciences in good conscience abandon a proven drug combination that has 100% cure rate in some patient populations with minimal side effects? This combination has also shown to be safe in people with cirrhosis and a very real candidate for use in the liver transplant population. What is Gilead doing about providing early access to these very sick people who may actually die before Gilead completes the drug studies necessary for an all-Gilead combination regimen?
Research By: Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Eley T, Wind-Rotolo M, Huang S-P, Gao M,McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, and Grasela DM for the AI444040 Study Group